Cost Effectiveness Of Linezolid In Central America

Ventilator Acquired Pneumonia Clinical Trial

Official title:
Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America

Status Withdrawn

Clinical Trial Summary

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01040585
Study type	Observational
Source	Pfizer
Contact
Status	Withdrawn
Phase	Phase 4
Start date	July 2010
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05487586` - Real-World Study of Ceftazidime Avibactam in China
Completed	`NCT01770015` - Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia	N/A
Completed	`NCT00332982` - Ontario ICU Clinical Best Practices Demonstration Project	N/A
Completed	`NCT01807884` - Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients	N/A
Completed	`NCT00938002` - Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients
Completed	`NCT01042353` - Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia	Phase 4